NeuroSense Therapeutics Aktie

Kaufen

Verkaufen

0,6050 EUR -0,0200 EUR -3,20 %

08:00:21

FSE

0,6450 USD -0,1090 USD -14,46 %

24.06.2026

BTT

Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Marktkap.23,90 Mio. EUR

Div. Rendite0,00%

WKNA3DFK1

ISINIL0011809592

SymbolNRSN

NeuroSense Therapeutics Aktien News

Sortieren:Datum Meistgelesen

08.01.26PR NewswireWorld-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

22.12.25PR NewswireNeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

04.12.25PR NewswireNeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

24.11.25PR NewswireNeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

03.11.25PR NewswireNeuroSense to Host Investor Webinar on December 8, 2025

06.10.25PR NewswireNeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

10.09.25PR NewswireNeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

04.09.25PR NewswireNeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

01.08.25PR NewswireNeuroSense Provides Business Update and Progress for the First Half of 2025

22.07.25PR NewswireAward-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

07.05.25PR NewswireNeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

24.04.25PR NewswireNeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

09.04.25PR NewswireNeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

09.04.25finanzen.netNeuroSense Therapeutics hat Bilanz für das abgelaufene Quartal gezogen

07.04.25PR NewswireNeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

04.04.25PR NewswireNeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

06.01.25PR NewswireNeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

23.12.24PR NewswireNeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

20.12.24finanzen.netNeuroSense Therapeutics: Quartalsergebnisse zum jüngsten Jahresviertel

18.12.24PR NewswireNeuroSense Provides Business Update and Third Quarter 2024 Financial Results

11.12.24PR NewswireNeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

04.12.24PR NewswireNeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

21.11.24PR NewswireNeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

28.10.24PR NewswireNeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

24.10.24PR NewswireNew Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

15.10.24PR NewswireNeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

09.10.24PR NewswireNeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

07.10.24PR NewswireNeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

24.09.24PR NewswireNeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

24.09.24PR NewswireNeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

30.08.24PR NewswireNeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

07.08.24PR NewswireNeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

01.08.24PR NewswireNeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

09.07.24PR NewswireNeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

01.07.24PR NewswireNeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a...

25.06.24finanzen.netNeuroSense Therapeutics hat Bilanz für das abgelaufene Quartal gezogen

24.06.24PR NewswireNeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

21.06.24PR NewswireNeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

20.05.24PR NewswireNeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

14.05.24PR NewswireNeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

NeuroSense Therapeutics News

NeuroSense Therapeutics News: auf dieser Seite finden Sie alle NeuroSense Therapeutics News und Nachrichten zur NeuroSense Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch NeuroSense Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um NeuroSense Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.